Evidence map›Paper›PMID 38143357›Full record

ArticleJournal of Alzheimer's disease : JAD2024

Rationale and Design of the "DIagnostic and Prognostic Precision Algorithm for behavioral variant Frontotemporal Dementia" (DIPPA-FTD) Study: A Study Aiming to Distinguish Early Stage Sporadic FTD from Late-Onset Primary Psychiatric Disorders.

Sterre C M de Boer, Lina Riedl, Chiara Fenoglio, Ishana Rue, Ramon Landin-Romero, Sophie Matis, Zac Chatterton, Daniela Galimberti, Glenda Halliday, Janine Diehl-Schmid and 3 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 5 countries.

Sterre C M de BoerAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.
Lina RiedlDepartment of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.
Chiara FenoglioDepartment of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
Ishana RueDepartment of Psychiatry, Douglas Mental Health University Institute, McGill University, Montreal, Canada.
Ramon Landin-RomeroFaculty of Medicine and Health, School of Health Sciences & Brain and Mind Sciences, The University of Sydney, Sydney, Australia.
Sophie MatisFaculty of Medicine and Health, School of Health Sciences & Brain and Mind Sciences, The University of Sydney, Sydney, Australia.
Zac ChattertonBrain and Mind Centre and Faculty of Medicine and Health School of Medical Sciences, The University of Sydney, Camperdown, NSW, Australia.
Daniela GalimbertiUniversity of Milan, Milan, Italy.
Glenda HallidaySchool of Medical Sciences & Brain and Mind Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Janine Diehl-SchmidDepartment of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.
Olivier PiguetSchool of Psychology and Brain & Mind Centre, The University of Sydney, Sydney, Australia.
Yolande A L PijnenburgAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.
Simon DucharmeDepartment of Psychiatry, Douglas Mental Health University Institute, McGill University, Montreal, Canada.
The University of Sydney · AUUniversity of Milan · ITAmsterdam Neuroscience · NLDouglas Mental Health University Institute · CAInn-Salzach-Klinikum · DEMontreal Neurological Institute and Hospital · CATechnical University of Munich · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe behavioral variant of frontotemporal dementia (bvFTD) is very heterogeneous in pathology, genetics, and disease course. Unlike Alzheimer's disease, reliable biomarkers are lacking and sporadic bvFTD is often misdiagnosed as a primary psychiatric disorder (PPD) due to overlapping clinical features. Current efforts to characterize and improve diagnostics are centered on the minority of genetic cases.

objectiveThe multi-center study DIPPA-FTD aims to develop diagnostic and prognostic algorithms to help distinguish sporadic bvFTD from late-onset PPD in its earliest stages.

methodsThe prospective DIPPA-FTD study recruits participants with late-life behavioral changes, suspect for bvFTD or late-onset PPD diagnosis with a negative family history for FTD and/or amyotrophic lateral sclerosis. Subjects are invited to participate after diagnostic screening at participating memory clinics or recruited by referrals from psychiatric departments. At baseline visit, participants undergo neurological and psychiatric examination, questionnaires, neuropsychological tests, and brain imaging. Blood is obtained to investigate biomarkers. Patients are informed about brain donation programs. Follow-up takes place 10-14 months after baseline visit where all examinations are repeated. Results from the DIPPA-FTD study will be integrated in a data-driven approach to develop diagnostic and prognostic models.

conclusionsDIPPA-FTD will make an important contribution to early sporadic bvFTD identification. By recruiting subjects with ambiguous or prodromal diagnoses, our research strategy will allow the characterization of early disease stages that are not covered in current sporadic FTD research. Results will hopefully increase the ability to diagnose sporadic bvFTD in the early stage and predict progression rate, which is pivotal for patient stratification and trial design.

Indexed as

AcetamidesFrontotemporal DementiaIsothiocyanatesBiomarkersHumansNeuropsychological TestsPrognosisProspective Studies2-(3,4-dichlorophenyl)-N-methyl-N-(1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl)ethyl)acetamideAcetamidesBiomarkersIsothiocyanatesAlzheimer’s diseasediagnosticsfrontotemporal dementianeurodegenerationprognosticspsychiatric disorders

Identifiers

PMID38143357
PMCPMC10836537
OpenAlexW4390102912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.